

NEW POLICY UPDATES
CLINICAL PAYMENT, CODING AND POLICY CHANGES

We regularly augment our clinical, payment and coding policy positions as part of our ongoing policy review processes. In an effort to keep our providers informed, please see the below chart of upcoming new policies.

Effective for dates of service beginning **(11/9/2020)**:

POLICY UPDATE

Bamlanivimab (Q0239) is currently available at no cost. On December 3rd, 2020, Texas Medicaid added Bamlanivimab and administration of **Bamlanivimab (M0239)** as benefits in response to the COVID-19 Emergency Use Authorization (EUA). It is an allowable drug for dates of service on or after Nov. 9, 2020.

Effective for dates of service beginning **(11/21/2020)**:

POLICY UPDATE

Casirivimab and Imdevimab (Q0243)

Beginning December 15th, 2020, Texas Medicaid added Casirivimab and Imdevimab (Q0243) and administration of Casirivimab and **Imdevimab (M0243)** as benefits in response to the COVID-19 Emergency Use Authorization (EUA). It is an allowable drug for dates of service on or after Nov. 21, 2020.